Andy

This September 19^th, the BioHealth Capital Region Investment Conference will once again serve as a premier gathering for the biopharma sector, uniting a dynamic blend of participants, including industry executives, investors, and exciting early-stage companies. Known for fostering impactful collaborations and driving innovation, the free-to-attend conference on the third day of BioHealth Capital Region Week is an essential event for those invested in the continued growth of the BioHealth Capital Region.

As part of this event, BioHealth Innovation (BHI) invites you to connect with our expert Analyst Team, led by Jon Nelson. This team plays a pivotal role in advancing the biohealth ecosystem by offering strategic insights within the non-dilutive funding space that help drive success for startups and established companies.

Attendees registered will have the unique opportunity to schedule one-on-one meetings with Jon Nelson. These sessions offer a chance to discuss non-dilutive funding, gain valuable guidance from a team deeply embedded in the grant landscape, and explore potential options for grant assistance. The BHI Analyst Team is equipped to provide the support you need to achieve your goals.

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., welcomes Brad Sibbald, Vice President of Kelly Science and Clinical, and Sarah Porter, Vice President of Government Solutions at Kelly Services. Together, they explore the critical trends and strategies shaping the biotech and government workforce landscapes, with a particular focus on the BioHealth Capital Region (BHCR).

Kelly Services, a global leader in workforce solutions, plays a pivotal role in connecting talent with opportunities across various industries, including science, engineering, technology, and telecommunications. Brad and Sarah provide valuable insights into how Kelly Services is adapting to the evolving needs of the biotech sector, from commercial enterprises to government agencies.

Listen now via your favorite podcasting platform:

Apple: https://apple.co/4dSL8N6
Spotify: https://spoti.fi/4e1sl2t
Amazon Music: https://amzn.to/3zLNbUw
TuneIn: https://bit.ly/2M60Wmx

The discussion covers various topics, including the current talent landscape in the BHCR, strategies for maintaining a robust pipeline, and the challenges of retaining top talent in an increasingly competitive market.

Additionally, we learn about Kelly’s upcoming virtual job fair in September (https://bit.ly/3yMuiRm), an event for those looking to connect with opportunities in the biotech sector and the 2024 Kelly Global Re:work Report (https://bit.ly/3SSVhBl), offering listeners valuable insights into the future of work and workforce trends globally.

By Sara Gilgore – Staff Reporter, Washington Business Journal Aug 21, 2024 – Sally Allain, the inaugural head of Johnson & Johnson Innovation’s D.C. incubator, has left her position after more than four years — to grow Virginia Tech’s health sciences research enterprise.

Allain, a longtime J&J exec who built up and led the local JLabs hub that planted roots on Children’s National Hospital’s Walter Reed campus in spring 2019, stepped away this month, announcing her departure in a LinkedIn post. She’ll start with Virginia Tech next week as chief health sciences growth and innovation officer, a newly created position charged with spinning out technology companies and tapping big-name partners across sectors.

FALLS CHURCH, Va.–(BUSINESS WIRE)–Retension Pharmaceuticals, Inc. is pleased to announce the successful closing of its Series A $10.4 million financing round to initiate a well-powered and controlled Phase 2 clinical study in patients with hypertension uncontrolled on two or more antihypertensives.

The Technology Transfer Society – Washington D.C. Chapter is excited to announce its Fall 2024 course, “Introduction to Technology Transfer and Commercialization,” offered in collaboration with Montgomery College. This hybrid course, available both virtually and in-person, is designed to provide students with a comprehensive overview of the technology transfer process—transitioning innovations from the lab to the marketplace.

Whether you’re interested in the inner workings of a technology transfer office or looking to commercialize your own invention, this course is an excellent opportunity to gain valuable insights. You’ll learn from seasoned professionals, including experts from federal labs, who will share their knowledge and experiences to help you navigate the complexities of technology transfer.

Natasha Sheybani, assistant professor of biomedical engineering at the University of Virginia School of Engineering, will collaborate with researchers at Children’s National Hospital to study the combination of two therapies for pediatric brain cancer. 

High-risk brain tumors in children often don’t respond well to existing chemotherapy and radiation treatments, but Sheybani and her collaborators hope their fusion of therapies will offer a better option.